About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
To download the full report, click here.
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) potential budget impact analyses are not very useful for private payers’ budget decisions. The whitepaper’s authors identify several weaknesses in ICER’s budget impact analysis, which they believe limits the usefulness of this approach for private payers.
Milliman Study on Limitations in Using ICER’s “Potential Budget Impact” Work to Guide Private Payer Budget Decisions image
Report
Economic Impact
Milliman Study on Limitations in Using ICER’s “Potential Budget Impact” Work to Guide Private Payer Budget Decisions
Milliman Study on Limitations in Using ICER’s “Potential Budget Impact” Work to Guide Private Payer Budget Decisions image